Kadimastem Past Earnings Performance
Past criteria checks 0/6
Kadimastem has been growing earnings at an average annual rate of 7.2%, while the Biotechs industry saw earnings growing at 12.5% annually.
Key information
7.2%
Earnings growth rate
42.6%
EPS growth rate
| Biotechs Industry Growth | -24.5% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kadimastem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -12 | 5 | 6 |
| 30 Sep 23 | 0 | -15 | 5 | 8 |
| 30 Jun 23 | 0 | -17 | 6 | 11 |
| 31 Mar 23 | 0 | -20 | 6 | 13 |
| 31 Dec 22 | 0 | -23 | 7 | 15 |
| 30 Sep 22 | 0 | -24 | 7 | 16 |
| 30 Jun 22 | 0 | -25 | 7 | 17 |
| 31 Mar 22 | 0 | -26 | 7 | 17 |
| 31 Dec 21 | 0 | -26 | 7 | 17 |
| 30 Sep 21 | 0 | -25 | 7 | 16 |
| 30 Jun 21 | 0 | -23 | 8 | 14 |
| 31 Mar 21 | 0 | -22 | 7 | 14 |
| 31 Dec 20 | 0 | -22 | 7 | 13 |
| 30 Sep 20 | 0 | -23 | 7 | 15 |
| 30 Jun 20 | 0 | -25 | 7 | 17 |
| 31 Mar 20 | 0 | -25 | 7 | 17 |
| 31 Dec 19 | 0 | -25 | 7 | 18 |
| 30 Sep 19 | 0 | -25 | 7 | 18 |
| 30 Jun 19 | 0 | -25 | 7 | 18 |
| 31 Mar 19 | 0 | -25 | 7 | 17 |
| 31 Dec 18 | 0 | -24 | 7 | 17 |
| 30 Sep 18 | 0 | -22 | 7 | 15 |
| 30 Jun 18 | 0 | -21 | 7 | 13 |
| 31 Mar 18 | 0 | -21 | 7 | 14 |
| 31 Dec 17 | 1 | -21 | 7 | 15 |
| 30 Sep 17 | 1 | -23 | 7 | 16 |
| 30 Jun 17 | 2 | -23 | 8 | 17 |
| 31 Mar 17 | 2 | -21 | 8 | 15 |
| 31 Dec 16 | 2 | -20 | 8 | 13 |
| 30 Sep 16 | 1 | -19 | 8 | 11 |
| 30 Jun 16 | 1 | -18 | 8 | 10 |
| 31 Mar 16 | 1 | -17 | 7 | 9 |
| 31 Dec 15 | 1 | -17 | 7 | 10 |
| 30 Sep 15 | 1 | -14 | 6 | 9 |
| 30 Jun 15 | 1 | -13 | 6 | 8 |
| 31 Mar 15 | 0 | -15 | 6 | 10 |
| 31 Dec 14 | 0 | -15 | 7 | 9 |
| 30 Sep 14 | 0 | -17 | 8 | 9 |
| 30 Jun 14 | 0 | -15 | 9 | 9 |
| 31 Mar 14 | 0 | -14 | 9 | 8 |
| 31 Dec 13 | 0 | -13 | 7 | 8 |
| 30 Sep 13 | 0 | -12 | 6 | 8 |
Quality Earnings: KDST is currently unprofitable.
Growing Profit Margin: KDST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KDST is unprofitable, but has reduced losses over the past 5 years at a rate of 7.2% per year.
Accelerating Growth: Unable to compare KDST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KDST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: KDST's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.